Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 08, 2024 11:59am
RE:CD8+ TiLs and T-cell exhaustion
" Patients with early-stage triple-negative breast cancer (TNBC) who had breast tissue with more tumor-infiltrating lymphocytes (TIL) and did not receive adjuvant or neoadjuvant chemotherapy
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 08, 2024 11:49am
RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
Challenges Faced by Antibody-Drug Conjugates Potential cancer resistance to ADCs Cancer cells can gradually develop mechanisms to resist ADCs, reducing their effectiveness over time. This
...more
(433)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Jun 08, 2024 11:37am
RE:RE:RE:I agree 109%….
Casey....check out Bucky's posting history....he's been posting since the mid 2022s, claiming that he's been a very large shareholder since about 2019, and he has done nothing but mock and
...more
(93)
•••
CaseyL
X
View Profile
View Bullboard History
Comment by
CaseyL
on Jun 08, 2024 10:44am
RE:RE:I agree 109%….
You doubt a significant bought deal would happen?
(211)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Jun 07, 2024 3:04pm
RE:RE:I agree 109%….
Pumpers been speculating on a buyout and price since god was a kid.
(157)
•••
fasttrack5
X
View Profile
View Bullboard History
Comment by
fasttrack5
on Jun 07, 2024 3:02pm
RE:I agree 109%….
Exactly CF and as stated previously a partnership or complete buyout is what I'm waiting on. Sooner the better for shareholders. Shazam would be this quarter or latest 3rd qrt. just sayin:) RJ
(1009)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Jun 07, 2024 2:10pm
I agree 109%….
It was stated in short message....something I'm ni5 good at lol. recappjng the points. they are waiting & expecting FDA type c meeting date/ follow up etc.....very soon. the first patient to
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 12:08pm
RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
ImmuoGen's only approval occurred as an Accelerated Approval in November 2022. Their follow-on confirmatory trial is MIRASOL: Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 12:00pm
RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
ImmuoGen's only approval occurred in November 2022, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinumresistant epithelial ovarian, fallopian tube, or primary
...more
(295)
•••
inthno
X
View Profile
View Bullboard History
Comment by
inthno
on Jun 07, 2024 11:23am
RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
Doing comparisons it would be nice if onc is being considered for a BO as opposed to a partnership as it ends all uncertainty surrounding the company. As to IMmunoGEn, I believe that they were worth
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 10:58am
RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
ImmunoGen has been around for 40 years ... before being acquired by Abbive this year for US$10.1 Billion.
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 10:23am
RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs
In February 2024, AbbVie closed a $10.1 billion deal acquiring ImmunoGen, an ADC-focused biotechnology company headquartered in suburban Boston. June 07, 2024 - Abbive reported on the
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 10:16am
RE:RE:RE:RE:RE:Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024
“The data from [ the Goblet Phase 2 PDAC Cohort study showed ] a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of
...more
(5649)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Jun 07, 2024 9:24am
RE:RE:RE:RE:Very I last few weeks, months
These are the nattering nancies of negativity who think that their irrationality is somehow funny.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
AirBoss of America Corp. Class Action Certification and Settlement
The Convenience of Modern Banking With the Benefits of Bitcoin Has Arrived
Xcyte Digital Corp. Announces Execution of Definitive Agreement with MCON Live Inc.